Variables | Cases (147) | Univariate | Multivariate | |||||
---|---|---|---|---|---|---|---|---|
Death | Survival | OR | IC95 % | p | OR | IC95 % | p | |
N (%) | N (%) | |||||||
Male gender | 20 (23.5) | 65 (76.5) | 1.81 | 0.76–4.30 | 0.21 | |||
ICU | 11 (52.4) | 10 (47.6) | 6.6 | 2.45–17.78 | <0.001 | 2.10 | 0.54–8.13 | 0.29 |
HAIs | 15 (25.0) | 45 (75.0) | 1.74 | 0.77–3.94 | 0.21 | |||
Charlson ≥ 3 | 15 (31.3) | 33 (68.7) | 2.76 | 1.20–6.34 | 0.03 | 0.68 | 0.17–2.74 | 0.59 |
Co-morb (liver disease) | 5 (71.4) | 2 (28.6) | 12.1 | 2.21–65.99 | 0.003 | 1.45 | 0.13–15.58 | 0.76 |
Co-morb (cancer) | 3 (75.0) | 1 (25.0) | 13.5 | 1.35–135.0 | 0.02 | 6.87 | 0.40–118.8 | 0.18 |
Co-morbidities (≥2) | 8 (66.7) | 4 (33.3) | 10.9 | 3.00–39.34 | <0.01 | 12.4 | 1.90–80.35 | 0.008 |
Deceased donor | 20 (24.1) | 63 (75.9) | 1.94 | 0.82–4.61 | 0.15 | |||
Induction therapy | 7 (22.6) | 24 (77.4) | 1.25 | 0.48–3.26 | 0.62 | |||
Acute rejection (AR) | 21 (48.8) | 22 (51.2) | 1.66 | 0.54–4.24 | 0.31 | |||
AR-corticosteroids | 6 (30.0) | 14 (70.0) | 1.94 | 0.67–5.58 | 0.23 | |||
OB-MMF | 5 (11.6) | 38 (88.4) | 0.44 | 0.15–1.24 | 0.17 | |||
OB-Ciclosporine | 16 (16.8) | 79 (83.2) | 0.61 | 0.27–1.39 | 0.28 | |||
Double-J | 4 (9.8) | 37 (90.2) | 0.35 | 0.11–1.08 | 0.07 | |||
Pre tx dialysis | 22 (17.1) | 107 (82.9) | 0.32 | 0.11–0.93 | 0.05 | 0.58 | 0.13–2.52 | 0.47 |
CMV | 4 (20.0) | 16 (80.0) | 1.02 | 0.31–3.32 | 1.00 | |||
Shock | 6 (46.2) | 7 (53.8) | 4.14 | 1.27–13.45 | 0.02 | 0.47 | 0.08–2.65 | 0.40 |
Respiratory failure | 15 (62.5) | 9 (37.5) | 13.0 | 4.79–35.14 | <0.001 | 13.2 | 3.07–57.19 | 0.001 |
Pre tx diabetes | 2 (13.3) | 13 (86.7) | 0.60 | 0.13–2.81 | 0.74 | |||
Inadequate atb | 12 (26.7) | 33 (73.3) | 1.82 | 0.78–4.21 | 0.18 |